Carlos Garberoglio, MD Chair, Surgery School of Medicine Head, Surgery, Surgical Oncology Division School of Medicine Professor, Surgery School of Medicine Professor, Basic Sciences School of Medicine

Research & Grantsmanship 

  Funded Research Project (PI)

• A randomized trial of axillary node dissection in women with clinical T1 or T2 NO M0 breast cancer who have a positive sentinel node. ( 4/2004 - 12/2004 )

• Study of tamoxifen and raloxifene (STAR) for the prevention of breast cancer. ( 4/1999 - 8/2004 )

• A randomized, phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. ( 9/2000 - 2/2004 )

• A clinical trial to evaluate the benefit of adding octreotide (SMS 201-995 pa LAR) to tamoxifen alone or to tamoxifen and chemo in patients with axillary node-negative, estrogen-receptor-positive, primary invasive breast cancer. ( 8/1997 - 12/1999 )

• A clinical trial to evaluate the worth of preoperative multimodality therapy (dFU-LV and RTX) in patients with operable carcinoma of the rectum. ( 12/1993 - 6/1999 )

• A clinical trial comparing short, intensive AC with or without tamoxifen with conventional CMF with or without tamoxifen in node-negative breast cancer patients with ER-negative tumors. ( 9/1991 - 12/1998 )

• A clinical trial to determine the worth of tamoxifen and the worth of breast radiation in the management of patients with node-negative, occult, invasive breast cancer treated by lumpectomy. ( 4/1987 - 12/1998 )

• A randomized trial evaluating the worth of paclitaxel (taxol) following doxorubicin (adriamycin)/cyclophosphamide in breast cancer patients with positive axillary nodes. ( 11/1995 - 5/1998 )

• A clinical trial to determine the worth of tamoxifen for preventing breast cancer. ( 11/1996 - 12/1997 )

• A clinical trial to evaluate the worth of tamoxifen in conjunction with lumpectomy and breast irradiation for the treatment of noninvasive intraductal carcinoma (DCIS) of the breast. ( 9/1992 - 4/1994 )

• A clinical trial to assess the relative efficacy of 5-FU + leuvorin with or without interferon alfa-2a in patients with dukes'' B and C carcinoma of the colon. ( 3/1992 - 2/1994 )

• A "unified" trial to compare short, intensive preoperative systemic adriamycin cyclophosphamide threapy with similary therapy administered in conventional postoperative fashion ( 9/1991 - 4/1993 )

• A clinical trial to determine the worth of chemotherapy and tamoxifen or tamoxifen alone in the management of patients with primary invasive breast cancer, negative, axillary nodes and estrogen-receptor-positive tumors. ( 9/1991 - 3/1993 )

• A phase III, adjuvant trial comparing three chemotherpay regiments in women with node-positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD. Paclitaxel; (DD AC followed by DD P) ( 10/2004 - Present )

• A phase III clinical trial comparing infusional 5-fluorouracil(5-FU), leucovorin, and oxaliplatin (mFOLFOX6). Every two weeks with bevacizumab to the same regimen without bevacizumab for the treatment of patients with resected stages II and III carcinoma. ( 9/2004 - Present )

• A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC), with or without celecoxib, in patients with node-negative breast cancer. ( 6/2004 - Present )

• Sentinel Lymph Node Working Group Data Acquisition Project ( 2/2004 - Present )

  Funded Research Project (CI)

• A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol (AC-T) to that of adriamycin and cyclophosphamide  followed by taxol plus herceptin (AC-T+HC) in node-positive breast cancer patients who have tumors. PI: Howard ( 4/2000 - 4/2005 )

• A study comparing adjuvant clodronate therapy with placebo in patients with early-stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy. PI: Howard ( 12/2002 - 3/2004 )

• A three-arm randomized trial to compare adjuvant adraimycin and cyclophosphamide followed by taxotere (AC-T); adriamycin and taxotere (AT); and adriamycin, taxotere, and cyclophosphamide (ATC) in breast cancer patients with positive axillary lymph nodes. PI: Howard ( 3/1999 - 3/2004 )

• A clinical trial comparing 5-fluorouracil (5-FU) plus leucovorin (LV) and oxaliplatin with 5-FU plus LV for the treatment of patients with stages II and III carcinoma of the colon. PI: Godfrey ( 5/2000 - 11/2002 )

• A trial evaluate the worth of serum ErbB-2 extracellular domain and serum ErbB-2 antibodies in predicting response to preoperative chemo and long term - term outcome in patients with operable breast cancer who are participating in NSABP protocol B-27. PI: Howard. ( 4/1997 - 12/2000 )

• A randomized trial comparing preoperative doxorubicin (adriamycin) cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel in patients with operable carcinoma of the breast. PI: Howard ( 3/1996 - 12/2000 )

• A clinical trial comparing oral uracil/ftorafur (UFT) plus lecovorin (LV) with 5 fluorouracil (5-FU) plus LV in the treatment of patients stages II and III carcinoma of the colon. PI: Wilbur ( 7/1997 - 3/1999 )

• A clinical trial comparing oral uracil/ftorafur(UFT) plus leucovorin (LV) with 5 fluorouracil(5-FU) plus LV in the treatment of patients stages II and III carcinoma of the colon. PI: Howard ( 4/1997 - 3/1999 )

• A phase I/II neoadjuvant study of capecitabine, irinotecan, celecoxib and radiation therapy in patients with locally advanced rectal cancer. PI: Malik ( 1/2003 - 7/0000 )

• A multicenter, prospective, blinded-reader study to determine the sensitivity and specificity of the comfort scan system to detect malignancy as an adjunct to mammography in patients 50 years of age. PI: Bae ( 5/2005 - Present )

• A clinical trial comparing anastrozole with tamoxifen  in postmenopausal patients with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy. PI: Howard ( 10/2003 - Present )